Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SI | P14410 | 1/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.37 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.37 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28153802 | 0.91 | SMN1; SMN2 (0.42) | ALDH1A1POLBLMNAHSD17B10OPRM1 | |
| SCHEMBL30148463 | 0.90 | SMN1; SMN2 (0.38) | ALDH1A1POLBLMNAHSD17B10OPRM1 | |
| SCHEMBL19348569 | 0.81 | POLB (0.43) | ALDH1A1POLBLMNAHSD17B10OPRM1 | |
| SCHEMBL11959804 | 0.79 | ALDH1A1 (0.47) | ALDH1A1POLBLMNASMN1; SMN2ATM | |
| SCHEMBL19348572 | 0.79 | POLB (0.35) | ALDH1A1POLBLMNAHSD17B10ALOX15 | |
| SCHEMBL19360778 | 0.79 | LMNA (0.35) | ALDH1A1POLBLMNAHSD17B10ALOX15 | |
| SCHEMBL19348553 | 0.78 | POLB (0.34) | ALDH1A1POLBLMNAHSD17B10ALOX15 | |
| SCHEMBL19216686 | 0.77 | SMN1; SMN2 (0.44) | ALDH1A1POLBSMN1; SMN2ALOX15TSHR | |
| SCHEMBL4979796 | 0.77 | MEN1 (0.36) | ALDH1A1POLBLMNAHSD17B10OPRM1 | |
| SCHEMBL2151136 | 0.77 | ALDH1A1 (0.39) | ALDH1A1POLBLMNAHSD17B10OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3134408-B1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME (US) | 2020-08-12 | — | — | EP | disclosed |
| US-10093683-B2 | Factor XIa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-10-09 | — | — | US | disclosed |
| EP-3134408-A1 | FACTOR XIa INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-03-01 | — | — | EP | disclosed |
| US-20170044183-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
| WO-2015164308-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-10-29 | — | — | WO | disclosed |
| US-20120040975-A1 | BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. | 2012-02-16 | — | — | US | disclosed |
| WO-2010114958-A1 | BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2010-10-07 | — | — | WO | disclosed |
| US-20050272732-A1 | 5-ethyl-imidazo (5,1-F) (1,2,4,) triazin-4 (3h)-ones as phosphodiesterase inhibitors | BAYER HEALTHCARE AG (DE) | 2005-12-08 | — | — | US | disclosed |
| EP-1504006-A1 | 5-ETHYL-IMIDAZO[5,1-F][1,2,4]TRIAZIN-4(3H)-ONES AS PHOSPHODIESTERASE INHIBITORS | Bayer Aktiengesellschaft (DE) | 2005-02-09 | — | — | EP | disclosed |
| WO-2003093270-A1 | 5-ETHYL-IMIDAZO (5,1-F) (1,2,4,) TRIAZIN-4 (3H) -ONES AS PHOSPHODIESTERASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044183-A1 | FACTOR XIa INHIBITORS | F11, SERPINC1, TFPI | ALDH1A1 3635/4885POLB 4698/4885LMNA 386/4885 |
| US-10093683-B2 | Factor XIa inhibitors | F11, F12, SERPINC1 | ALDH1A1 3478/4885POLB 4654/4885LMNA 394/4885 |
| US-20050272732-A1 | 5-ethyl-imidazo (5,1-F) (1,2,4,) triazin-4 (3h)-ones as phosphodiesterase inhibitors | PDE3A, PDE5A, PDE3B | ALDH1A1 754/4885POLB 2121/4885LMNA 2369/4885 |
| US-20120040975-A1 | BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, BDKRB2, GLP1R | ALDH1A1 1743/4885POLB 4285/4885LMNA 2033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.